ClinicalTrials.gg
CompletedNCT00456521Updated Dec 17, 2014Results posted

A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program

A Phase 3 interventional study of Naltrexone SR 32 mg/ bupropion SR 360 mg/ day and Placebo in Obesity and Overweight, sponsored by Orexigen Therapeutics, Inc. Completed at 9 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-12-17.

Sponsored by Orexigen Therapeutics, Inc · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
793
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing naltrexone in Obesity — 4 open to participants now, 4 under way, none of them phase 3. Naltrexone · Obesity.

Enrollment
4th of 23
793 · median 67
Started
2007
with 4 others
Phase 3
6 of 23
none open now
Registered
2nd of 23
by date
Lead sponsor
10 of 23
Orexigen Therapeutics, Inc

Among the 23 studies testing naltrexone in Obesity, this one is the 4th largest by enrollment, is one of 5 that started in 2007, is one of 6 in phase 3, and was the 2nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 23 studies testing naltrexone in Obesity are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About naltrexone

Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing naltrexone in Obesity, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether a combination of naltrexone SR and bupropion SR is safe and effective in treating obesity and leads to greater weight loss when given with a group lifestyle modification program than with group lifestyle modification alone.

Read the detailed description

The combination of group lifestyle modification counseling and pharmacotherapy has recently been shown to result in nearly twice the average weight loss at one year (12.1 kg) as pharmacotherapy alone (sibutramine, 5.0 kg) or lifestyle modification counseling alone (6.7 kg). Combining pharmacotherapy with a comprehensive program of diet, exercise and group lifestyle modification counseling may provide the best weight loss regimen. This study evaluated weight loss in subjects participating in such a comprehensive program who received a combination of naltrexone SR and bupropion SR, or placebo.

03

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Obesity
  • Behavior Modification
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female or male subjects aged 18 to 65 years (inclusive)
  • (weight [kg]/height [m²]) ≥30 and ≤45 kg/m² for subjects with uncomplicated obesity, and BMI of ≥27 and ≤45 kg/m² for subjects with controlled hypertension and/or dyslipidemia
  • Non-smoker and had not used tobacco or nicotine products for at least 6 months before screening
  • Normotensive (systolic ≤140 mm Hg and diastolic ≤90 mm Hg). Anti-hypertensive medications were allowed with the exception of alpha-adrenergic blockers, beta-blockers, and clonidine. Medical regimen was to be stable for at least 8 weeks.
  • Low-density lipoprotein level \<190 mg/dL and triglycerides level \<400 mg/dL. Medications for the treatment of dyslipidemia were allowed as long as the medical regimen had been stable for at least 8 weeks.
  • No abnormality of serum albumin, blood urea nitrogen (BUN), creatinine, , calcium and phosphorus
  • (ALT) and aspartate aminotransferase (AST) within 2.5 times (ULN)
  • No clinically significant abnormality of hematocrit, white blood cell (WBC) count, WBC differential, or
  • Fasting glucose ≤126 mg/dL and not receiving hypoglycemic agents
  • No clinically significant abnormality on urinalysis
  • Thyroid stimulating hormone (TSH) within 1.5 times ULN or normal triiodothyronine (T3), if TSH was below normal limits
  • Female subjects of had a negative serum pregnancy test
  • An IDS-SR score \<2 on individual items: 5 (sadness), 6 (irritability), 7 (anxiety/tension), and 18 (suicidality) and an IDS-SR total score \<30
  • Female subjects of childbearing potential were non-lactating and agreed to continue to use effective throughout the study and 30 days after discontinuation of study drug
  • Completed a food diary for 6 of 7 consecutive days during screening
  • Able to comply with all required study procedures and schedule
  • Able to speak and read English
  • Provided written

Exclusion criteria

Exclusion Criteria:

  • Obesity of known endocrine origin (e.g., untreated hypothyroidism, Cushing's syndrome, established polycystic ovary syndrome)
  • Serious medical condition (including but not limited to renal or hepatic insufficiency; congestive heart failure, angina pectoris, myocardial infarction, stroke, claudication, or acute limb ischemia; history of with exception of non-melanoma skin cancer or surgically cured cervical cancer)
  • Serious psychiatric illness (e.g., lifetime history of bipolar disorder, schizophrenia or other psychosis, bulimia, and anorexia nervosa; current serious personality disorder, e.g., borderline; severe major depressive disorder, recent [previous 6 months] suicide attempt or current active suicidal ideation, recent hospitalization due to psychiatric illness)
  • Response to the bipolar disorder questions that indicated the presence of bipolar disorder.
  • Required medications for the treatment of a psychiatric disorder (with the exception of short-term insomnia) within the previous 6 months
  • History of drug or alcohol abuse or dependence within 1 year
  • Type I or Type II diabetes mellitus
  • Baseline with a (QTc) interval (using Bazett's formula >450 millisecond (msec) [males] and >470 msec [females]) or the presence of any cardiac abnormalities, including but not limited to patterns consistent with myocardial ischemia, electrolyte abnormalities, or atrial or ventricular dysrhythmia or significant conduction abnormalities
  • Received excluded concomitant medications: any psychotropic agents (including antipsychotic, antidepressant, anxiolytic, mood stabilizer or anticonvulsant agents) with the exception of low-dose benzodiazepine or hypnotic agents for the treatment of insomnia; any anorectic or weight loss agents; any over-the-counter dietary supplements with psychoactive, appetite or weight effects; alpha-adrenergic blockers; beta-blockers; clonidine; coumadin; theophylline; cimetidine; oral ; topiramate, Depo-Provera®; smoking cessation agents; regular use of opioid or opioid-like analgesics
  • History of surgical or device (e.g., lap band) intervention for obesity
  • History of seizures of any etiology, or of predisposition to seizures (e.g., history of cerebrovascular accident, head trauma with >5 minutes loss of consciousness, concussion symptoms lasting >15 minutes, brain surgery, skull fracture, subdural hematoma, or febrile seizures)
  • History of treatment with bupropion or naltrexone within the preceding 12 months
  • History of or intolerance to bupropion or naltrexone
  • Used drugs, herbs, or dietary supplements believed to significantly affect body weight or participated in a weight loss management program within one month prior to baseline
  • Loss or gained >4.0 kilograms within the previous 3 months
  • Females who were pregnant or breast-feeding or planning to become pregnant during the study period or within 30 days of discontinuing study drug
  • Planned surgical procedure that could impact the conduct of the study
  • Received any drug or used an experimental device or procedure within the previous 30 days
  • Participated in any previous clinical trial conducted by Orexigen
  • Had any condition that in the opinion of the investigator made the subject unsuitable for inclusion into the study
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
793 participants (actual)

Study arms

  • Experimental
    NB32

    Naltrexone SR 32 mg/ bupropion SR 360 mg/ day with intensive group lifestyle modification counseling

    Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day · Behavioral: Intensive group lifestyle modification counseling

  • Placebo comparator
    Placebo

    Placebo with intensive group lifestyle modification counseling

    Drug: Placebo · Behavioral: Intensive group lifestyle modification counseling

Interventions

  • DrugNaltrexone SR 32 mg/ bupropion SR 360 mg/ day

    Drug page: Naltrexone

    Also known as: NB32

  • DrugPlacebo
  • BehavioralIntensive group lifestyle modification counseling
06

What researchers measure

Primary outcomes

  1. Co-primary: Body Weight- Mean Percent Change

    Time frame: Baseline, 56 weeks

  2. Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease

    Time frame: Baseline, 56 weeks

Secondary outcomes

  1. Body Weight- Proportion of Subjects With ≥10% Decrease

    Time frame: Baseline, 56 weeks

  2. Change in Waist Circumference

    Time frame: Baseline, 56 weeks

  3. Change in Fasting Triglycerides Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  4. Change in Fasting Insulin Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  5. Change in Fasting HDL Cholesterol Levels

    Time frame: Baseline, 56 weeks

  6. Change in IWQOL-Lite Total Scores

    IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

    Time frame: Baseline, 56 weeks

  7. Change in HOMA-IR Levels, Using Log-transformed Data

    HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

    Time frame: Baseline, 56 weeks

  8. Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data

    Time frame: Baseline, 56 weeks

  9. Change in Fasting Blood Glucose Levels

    Time frame: Baseline, 56 weeks

  10. Change in Fasting LDL Cholesterol

    Time frame: Baseline, 56 weeks

  11. Change in Systolic Blood Pressure

    Time frame: Baseline, 56 weeks

  12. Change in Diastolic Blood Pressure

    Time frame: Baseline, 56 weeks

  13. Change in IDS-SR Total Scores

    IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

    Time frame: Baseline, 56 weeks

  14. Change in Food Craving Inventory Sweets Subscale Scores

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

  15. Change in Food Craving Inventory Carbohydrates Subscale Scores

    The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

    Time frame: Baseline, 56 weeks

  16. Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire

    Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

    Time frame: Baseline, 56 weeks

07

Results

Posted Nov 21, 2014

Participant flow

Participant flow — Overall Study
MilestoneNB32Placebo
Started591202
Completed342118
Not completed24984
Withdrew: Adverse event15025
Withdrew: Withdrawal by subject4324
Withdrew: Lost to follow-up2217
Withdrew: Lack of efficacy36
Withdrew: Protocol violation40
Withdrew: Pregnancy11
Withdrew: Drug non-compliance, moved, other2611

Outcome measures

PrimaryCo-primary: Body Weight- Mean Percent Change
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percentage of body weight
Co-primary: Body Weight- Mean Percent Change
percentage of body weightNB32Placebo
Co-primary: Body Weight- Mean Percent Change-9.29 ± 0.40-5.08 ± 0.60
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -4.21 · 95% CI -5.56 to -2.86
PrimaryCo-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease
percentage of participantsNB32Placebo
Co-primary: Body Weight- Proportion of Subjects With ≥5% Decrease66.39 (62.17 to 70.61)42.49 (35.51 to 49.46)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.89 · 95% CI 2.02 to 4.13
SecondaryBody Weight- Proportion of Subjects With ≥10% Decrease
Time frame:
Baseline, 56 weeks
Reported as:
Number · percentage of participants
Body Weight- Proportion of Subjects With ≥10% Decrease
percentage of participantsNB32Placebo
Body Weight- Proportion of Subjects With ≥10% Decrease41.49 (37.10 to 45.89)20.21 (14.54 to 25.87)
Statistical analysis
  • NB32 vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 2.92 · 95% CI 1.95 to 4.37
SecondaryChange in Waist Circumference
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · cm
Change in Waist Circumference
cmNB32Placebo
Change in Waist Circumference-9.98 ± 0.48-6.77 ± 0.75
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): -3.21 · 95% CI -4.82 to -1.60
SecondaryChange in Fasting Triglycerides Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Triglycerides Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Triglycerides Levels, Using Log-transformed Data-16.62 (-19.66 to -13.47)-8.51 (-13.67 to -3.03)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.004 · Mean difference (net): -8.11
SecondaryChange in Fasting Insulin Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in Fasting Insulin Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in Fasting Insulin Levels, Using Log-transformed Data-27.98 (-32.36 to -23.31)-15.45 (-23.29 to -6.81)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.003 · Mean difference (net): -12.53
SecondaryChange in Fasting HDL Cholesterol Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting HDL Cholesterol Levels
mg/dLNB32Placebo
Change in Fasting HDL Cholesterol Levels4.10 ± 0.510.87 ± 0.80
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = <0.001 · Mean difference (net): 3.23 · 95% CI 1.52 to 4.95
SecondaryChange in IWQOL-Lite Total Scores

IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IWQOL-Lite Total Scores
units on a scaleNB32Placebo
Change in IWQOL-Lite Total Scores13.43 ± 0.5610.29 ± 0.86
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.001 · Mean difference (net): 3.14 · 95% CI 1.23 to 5.04
SecondaryChange in HOMA-IR Levels, Using Log-transformed Data

HOMA-IR= Homeostasis Model Assessment-Insulin Resistance

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in HOMA-IR Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in HOMA-IR Levels, Using Log-transformed Data-29.93 (-34.59 to -24.93)-16.56 (-25.02 to -7.14)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.003 · Mean difference (net): -13.37
SecondaryChange in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · percent change
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data
percent changeNB32Placebo
Change in High-sensitivity C Reactive Protein (Hs-CRP) Levels, Using Log-transformed Data-25.87 (-32.58 to -18.49)-16.89 (-28.31 to -3.66)
Statistical analysis
  • NB32 vs Placebo · ANCOVA · p = 0.165 · Mean difference (net): -8.98
SecondaryChange in Fasting Blood Glucose Levels
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting Blood Glucose Levels
mg/dLNB32Placebo
Change in Fasting Blood Glucose Levels-2.36 ± 0.62-1.08 ± 0.96
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -1.28 · 95% CI -3.34 to 0.79
SecondaryChange in Fasting LDL Cholesterol
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mg/dL
Change in Fasting LDL Cholesterol
mg/dLNB32Placebo
Change in Fasting LDL Cholesterol5.43 ± 1.368.13 ± 2.13
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -2.70 · 95% CI -7.26 to 1.86
SecondaryChange in Systolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mmHg
Change in Systolic Blood Pressure
mmHgNB32Placebo
Change in Systolic Blood Pressure-1.32 ± 0.47-3.87 ± 0.71
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 2.55 · 95% CI 0.97 to 4.14
SecondaryChange in Diastolic Blood Pressure
Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · mmHg
Change in Diastolic Blood Pressure
mmHgNB32Placebo
Change in Diastolic Blood Pressure-1.41 ± 0.33-2.78 ± 0.50
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 1.37 · 95% CI 0.25 to 2.49
SecondaryChange in IDS-SR Total Scores

IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression.

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in IDS-SR Total Scores
units on a scaleNB32Placebo
Change in IDS-SR Total Scores0.09 ± 0.23-0.00 ± 0.35
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): 0.09 · 95% CI -0.70 to 0.87
SecondaryChange in Food Craving Inventory Sweets Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Sweets Subscale Scores
units on a scaleNB32Placebo
Change in Food Craving Inventory Sweets Subscale Scores-2.54 ± 0.22-2.43 ± 0.33
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -0.11 · 95% CI -0.85 to 0.63
SecondaryChange in Food Craving Inventory Carbohydrates Subscale Scores

The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome).

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Food Craving Inventory Carbohydrates Subscale Scores
units on a scaleNB32Placebo
Change in Food Craving Inventory Carbohydrates Subscale Scores-2.06 ± 0.20-1.97 ± 0.31
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -0.09 · 95% CI -0.78 to 0.60
SecondaryChange in Question 19 From 21-Item COE (Control of Eating) Questionnaire

Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult

Time frame:
Baseline, 56 weeks
Reported as:
Least squares mean · units on a scale
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire
units on a scaleNB32Placebo
Change in Question 19 From 21-Item COE (Control of Eating) Questionnaire-13.75 ± 1.17-8.46 ± 1.75
Statistical analysis
  • NB32 vs Placebo · Mean difference (net): -5.29 · 95% CI -9.16 to -1.42

Adverse events

Collected over Baseline, 56 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NB32—22/584 (3.8%)465/584 (79.6%)
Placebo—1/200 (0.5%)132/200 (66%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventNB32Placebo
CholecystitisHepatobiliary disorders4/5840/200
Tibia fractureInjury, poisoning and procedural complications0/5841/200
CellulitisInfections and infestations2/5840/200
Atrial flutterCardiac disorders1/5840/200
Epiploic appendagitisGastrointestinal disorders1/5840/200
Non-cardiac chest painGeneral disorders1/5840/200
Biliary colicHepatobiliary disorders1/5840/200
Bacterial infectionInfections and infestations1/5840/200
Bronchitis acuteInfections and infestations1/5840/200
Bursitis infectiveInfections and infestations1/5840/200
Most frequent other events
Showing 10 of 20
Most frequent other events
EventNB32Placebo
NauseaGastrointestinal disorders199/58421/200
ConstipationGastrointestinal disorders141/58428/200
HeadacheNervous system disorders139/58435/200
DizzinessNervous system disorders85/5849/200
VomitingGastrointestinal disorders64/58413/200
Upper respiratory tract infectionInfections and infestations38/58418/200
InsomniaPsychiatric disorders51/58412/200
Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders29/58417/200
Dry mouthGastrointestinal disorders47/5846/200
DiarrhoeaGastrointestinal disorders43/58415/200

Baseline characteristics

All randomized subjects

Age, Continuous
Age, Continuous(years)NB32PlaceboTotal
Mean45.89 ± 10.4245.59 ± 11.3545.82 ± 10.66
Sex: Female, Male
Sex: Female, Male(Participants)NB32PlaceboTotal
Female528185713
Male631780
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NB32PlaceboTotal
White405149554
Black or African American14544189
Asian628
Native Hawaiian or Other Pacific Islander101
American Indian or Alaska Native718
Other27633
Weight
Weight(kg)NB32PlaceboTotal
Mean100.16 ± 15.42101.88 ± 14.96100.60 ± 15.31
BMI
BMI(kg/m^2)NB32PlaceboTotal
Mean36.34 ± 4.1636.96 ± 4.1836.50 ± 4.17
08

Study locations

9 sites
  • University of California, San Diego: Dept of Family & Preventive Medicine
    La Jolla, California 92093, United States
  • Center for Human Nutrition, University of Colorado Health Services Center
    Denver, Colorado 80220, United States
  • Univ. of Florida, College of Public Health, and Health Professions
    Gainesville, Florida 32611, United States
  • Washington Univ. Center for Human Nutrition
    St. Louis, Missouri 63110, United States
  • New York Obesity Research Center, St. Luke's-Roosevelt Hospital Center
    New York, New York 10025, United States
  • Center for Weight and Eating Disorders, School of Med., University of Penn.
    Philadelphia, Pennsylvania 19104, United States
  • Center for Obesity Research and Education, Temple University
    Philadelphia, Pennsylvania 19140, United States
  • Medical University of S. Carolina Weight Management Center
    Charleston, South Carolina 29425, United States
  • Behavioral Medicine Research Center
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Wadden TA, Foreyt JP, Foster GD, Hill JO, Klein S, O'Neil PM, Perri MG, Pi-Sunyer FX, Rock CL, Erickson JS, Maier HN, Kim DD, Dunayevich E. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011 Jan;19(1):110-20. doi: 10.1038/oby.2010.147. Epub 2010 Jun 17. PubMed 20559296 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2007, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 5 years 11 months after primary completion. A results delay was requested in Oct 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2007
First posted
Apr 5, 2007
Start
Mar 2007
Primary completionActual
Dec 2008
CompletionActual
Dec 2008
Results delay requested
Oct 30, 2012
Results first posted
Nov 21, 2014
Last update
Dec 17, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00456521
Lead sponsor
Orexigen Therapeutics, Inc
Responsible party
Sponsor
First posted
Apr 5, 2007
Start date
Mar 2007
Primary completion
Dec 2008
Completion
Dec 2008
Results posted
Nov 21, 2014
Last update
Dec 17, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion